NHS begins cancer injection that reduces hospital time to minutes

Serviço Nacional of Saúde of Reino Unido has begun offering a new injectable form of the drug Keytruda that dramatically reduces patient length of stay in the hospital during cancer treatment. Antes, the intravenous infusion took over an hour. Agora injection is administered within minutes, saving healthcare professionals time and allowing patients to spend fewer hours in oncology clinics.

Shirley Xerxes, 86 years old, resident of St Albans, in Hertfordshire, was one of the first people in Reino Unido to receive the injectable form in Centro of Câncer Mount Vernon, next to Watford. Ela reported that the procedure only took a few minutes compared to the hour or more he faced previously. The reduction allowed her to have more time for her personal activities, such as gardening.

Medicamento already treats 14 types of cancer

Keytruda, the brand name for pembrolizumab, is an immunotherapy medication that stimulates the body’s immune system to attack cancer cells. No Reino Unido, it is already approved to treat 14 different types of cancer, including:

• Lung Câncer
• Câncer head and neck
• Câncer of cervix
• Câncer breast
• Câncer skin
• Outros types approved for treatment

Aproximadamente 14 thousand patients in Inglaterra start treatment with Keytruda each year, and the majority of them are expected to switch to the injectable version. The medicine will be administered every three weeks as a one-minute injection or every six weeks as a two-minute injection, depending on each patient’s specific diagnosis.

Como immunotherapy works

Cancer can hide from the body’s immune system by producing proteins that send a stop signal, instructing immune cells not to attack. Immunotherapy blocks this signal, allowing cancer cells to be recognized and destroyed more easily. Essa scientific discovery was so significant that it earned researchers James Allison and Tasuku Honjo the Prêmio Nobel from Medicina in 2018.

Keytruda was one of the first drugs of its kind to be approved, initially for skin cancer and later expanded to other forms of the disease. It is currently the best-selling prescription medicine in the world, with global sales estimated at $30 billion by 2025.

Leia Também

Lake isolated 12 thousand years ago is home to millions of unique jellyfish on the planet

Two X-class solar flares hit Earth in seven hours and disrupt radio

Steam Controller arrives with innovative trackpads and user-serviceable design

Economia of hospital space and resources

NHS National Clinical Director for Cancer England, Prof. Peter Johnson, highlighted that switching to a standard, rapid injection will save significant time and benefit patients. Gerenciar Cancer treatment requires regular trips to the hospital, which can be extremely exhausting. Reduzindo administration time, the NHS will be able to free up space in chemotherapy units and begin offering treatment in the community, outside of hospitals.

The injection represents the third immunotherapy medicine of its kind that can be administered by injection on the NHS. Outro treatment, Opdivo or nivolumab, in a new injectable form, was introduced in some hospitals last year, demonstrating the NHS’s trend towards more efficient methods.

Custo kept confidential

NHS England has not disclosed the exact cost of the new injectable form to the health service, saying its agreement with US pharmaceutical company Merck Sharp & Dohme is confidential. Compreende However, it is clear that the NHS will pay practically the same price for both versions of the medicine. Keytruda has generated total sales estimated at $180 billion since its launch more than a decade ago, establishing itself as one of the most financially successful medicines of all time.

The patents protecting the original medicine expire in 2028 in the Estados Unidos and in 2031 in the Europa. Isso means competing companies could soon copy the formula and produce generic versions at lower prices. Nos US critics, including Democratic senator Elizabeth Warren, accused MSD of introducing the injectable form, protected by different patents, in part as a strategy to protect against future generic competition.

Benefícios clinical confirmed

MSD says the injection offers significant benefits to hospitals and patients by reducing time spent administering the medicine and freeing up time for other clinical tasks. Essa change has the potential to ease pressure on NHS resources, allowing the charity to care for more patients more efficiently. The testimony of patients like Shirley Xerxes demonstrates the positive impact on quality of life during cancer treatment.